Delirium Market Size to Reach USD 493.07 Mn by 2032

According to analysts at Vantage Market Research, the Global Delirium Market size is worth USD 315.1 Million in 2023 and is projected to reach USD 493.07 Million by 2032, growing at a CAGR (Compound Annual Growth Rate) of 5.1% from 2024 to 2032. The market is driven by an increasing aging population, enhanced methods for identifying and diagnosing conditions, and advancements in technology.

Market Overview

As the global shifts towards an increasing aging population, the incidence of delirium rises. According to the World Health Organization (WHO), the global population aged 60 and older is expected to grow from 1 billion in 2020 to 1.4 billion by 2030, and reach 2.1 billion by 2050. Additionally, the number of people aged 80 and above will increase by 426 million between 2020 and 2050. Older individuals are more vulnerable to delirium due to factors like existing health conditions, cognitive decline, multiple medications, and frequent hospitalizations. Delirium risk is further increased by age-related physiological changes, such as neurotransmitter imbalances and diminished cognitive function.

Telemedicine and remote monitoring significantly improve the management of delirium, especially for patients who live in underserved or rural areas who may find it difficult to get to medical institutions. By use of remote consultations, these technologies provide prompt interventions and early diagnosis and identification of delirium symptoms through routine evaluations. Healthcare practitioners can enhance patient outcomes by creating personalized treatment plans based on real-time data through the facilitation of a multidisciplinary approach.

FDA Approves Otsuka's ABILIFY ASIMTUFII for Schizophrenia, Delirium, and Bipolar I Disorder Maintenance Therapy

• In April 2023, Otsuka Pharmaceutical Co., Ltd. (Japan) received approval from the U.S. Food and Drug Administration (FDA) for ABILIFY ASIMTUFII (aripiprazole), a medication approved for treating schizophrenia, delirium, and as a maintenance monotherapy for individuals with bipolar I disorder. Additionally, it is effective in managing symptoms of delirium

Key Takeaways from the Report

• In 2023, North America dominated the market with 41.2% market share. The market is driven by an aging population and an increase in chronic diseases.
• Based on the Type, Hypoactive category accounted for significant market share in 2023. The increasing recognition of hypoactive delirium, characterized by reduced motor activity and lethargy, as a critical condition that requires effective management
• By Diagnosis and Treatment, Diagnosis dominated the market with largest market share of 62.3%. The growth of diagnosis segment is attributed to the integration of artificial intelligence and machine learning algorithms, which are transforming diagnostic methods by providing more efficient and objective evaluations

Top Companies

• Otsuka Pharmaceutical Co. Ltd
• Mylan N.V
• Teva Pharmaceutical Industries Ltd
• Zydus Group
• Glenmark Pharmaceuticals Ltd
• Pfizer
• Novartis AG

Report Coverage

Our market research reports provide comprehensive insights that are essential for strategic decision-making. We cover all key aspects of the market, including dynamics such as drivers, restraints, opportunities, and challenges, alongside the latest industry trends. Our analysis includes an in-depth technology roadmap, product life cycle evaluation, and PESTLE analysis, ensuring a thorough understanding of the market environment. We also assess GDP growth outlooks, examine regional market landscapes, and evaluate the impact of major events like the COVID-19 pandemic. Additionally, our reports feature a detailed competitive landscape, including company market shares and profiles, providing actionable intelligence to empower your business strategies.

Latest News

FDA Grants Approval to Teva's UZEDY, a Long-Acting Injectable for Schizophrenia and Delirium Treatment

• In April 2023, The FDA has approved UZEDY (risperidone), developed by Teva Pharmaceutical Industries. UZEDY is a long-acting injectable antipsychotic designed to treat schizophrenia and delirium in adults, particularly benefiting physically ill patients by alleviating the behavioral and cognitive symptoms of delirium